Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.

Yannan ZhaoNing XieWei LiWenyan ChenZheng LvYabing ZhengTao SunJieqiong LiuJian ZhangShihui HuYajun WangChengcheng GongYi LiYizhao XieRui GeFei XuBi-Yun Wang

Published in: Therapeutic advances in medical oncology (2021)

Eribulin was effective with a manageable toxicity profile in clinical practice. Furthermore, when prescribed in combination with other agents, eribulin did not increase the toxic effects of each agent. Eribulin monotherapy or plus other agents is an alternative for the heavily pretreated patients with MBC.

Keyphrases

metastatic breast cancer
clinical practice
randomized controlled trial
systematic review
cross sectional
clinical trial
combination therapy